CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Comparison of empirical antibiotics in covid19 pneumonia

Author: 
Onur BAYRAKÇI and Halim BAYRAM
Subject Area: 
Health Sciences
Abstract: 

Covid-19 disease is a fatal viral respiratory disease caused by the SARS-CoV-2 virus. A wide range of clinical findings are seen, from asymptomatic to death. Therefore, it has been observed that empirical antibiotics were frequently used in hospitalizations due to secondary coinfection concerns. The data of 1186 hospitalized patients were analyzed retrospectively.4 groups(30 patients per group) consisting of a total of 120 patients were formed homogeneously. All patients who fulfilled the criteria(Covid PCR test positive, diagnosed with pneumonia, treated with Favipiravir, normal white blood cell and neutrophil, didn’t have bacterial infection, didn’t receive anti-inflammatory and steroid-derived drug) were included in the study. Data of all patients (age, gender, comorbidity, laboratory parameters, tomography reports, antibiotic and other drugs, need for intensive care and mortality) were evaluated retrospectively. The first group was levofloxacin, the second group combination of levofloxacin and ceftriaxone, the third group combination of levofloxacin and piperacillin tazobactam, and the fourth group combination of levofloxacin and meropenem. Combination treatment with levofloxacin ceftriaxone and levofloxacin meropenem is more effective in patients with comorbidities. Levofloxacin meropenem or levofloxacin ceftriaxone treatment in patients with interstitial pneumonia and levofloxacin or levofloxacin piperacillin tazobactam treatment in patients with lobular pneumonia is more effective.Levofloxacin ceftriaxone treatment is more effective on the decrease in CRP value,but there is no statistically significant difference between all treatments (p<0.05). Levofloxacin decreases hospital stay more than levofloxacin meropenem. Levofloxacin ceftriaxone decrease hospital stay more than levofloxacin piperacillin tazobactam and levofloxacin meropenem (p<0.05).There is no statistically significant difference between levofloxacin and levofloxacin ceftriaxone as length of hospital stay. Treatment cost sare have been found as levofloxacin

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran